Kornimate/medical-research-clean huggingface dataset:
adapting the shed-meds deprescribing intervention to dementia care in assisted living

Conditions: Polypharmacy; Dementia; Quality of Life

Summary: this single-arm pilot study will evaluate the effects of an intervention to reduce exposure to unnecessary or potentially harmful medications among residents with dementia living in an assisted living facility. the goal of the intervention is to safely deprescribe medications (defined by dose reductions and stopped medications), based on a combination of clinical criteria and resident/surrogate preferences. the investigators will evaluate the effects of the intervention on the total number of medications deprescribed from enrollment at 30, 60, and 90 days along with resident/surrogate reports of quality of life at enrollment and 90 days.

this single-arm pilot trial will evaluate an evidence-based, patient-centered deprescribing intervention with assisted living facility (alf) residents age 65+ who have a diagnosis of dementia. this deprescribing intervention was demonstrated to be safe and effective in reducing medication burden during the shed-meds randomized clinical trial that enrolled hospitalized older adults discharging to post-acute care facilities. the intervention includes a comprehensive review of a participant's medications by the study's clinician and deprescribing recommendations using evidence-based guidelines. deprescribing recommendations will be shared with residents/surrogate decision makers (i.e., respective family member/s) to determine their willingness to stop or reduce the dose of the targeted medications. if the resident/surrogate-decision maker agrees, deprescribing recommendations will then be communicated with the routine alf medical providers for consideration and final deprescribing decisions.

Eligibility criteria:
inclusion criteria: * resident of assisted living facility * speaks english (due to interview-based assessments) * diagnosis of dementia * taking a total of 5 medications or at least one potentially inappropriate medication (defined by the beers criteria, stopp criteria, and the rationalization of home medication by an adjusted stopp in older patients \[rasp\]) * able self-consent or has a proxy (surrogate) exclusion criteria: - none

Keywords: deprescribing
a pilot randomized controlled trial for hand osteoarthritis

Conditions: Hand Osteoarthritis

Summary: this is a study involving people receiving care at the michael e. debakey va medical center, houston texas. we are studying people who have hand osteoarthritis (the most common form of arthritis that involves the hand) and testing treatments for the condition with the hope that we can help to improve hand pain as well as limit the damage that occurs related to the arthritis. people who choose to participate, are randomly assigned to one of two treatments, both expected to be helpful.

the research will be conducted at the following location(s): baylor college of medicine, baylor st. luke's medical center (bslmc), and michael e. debakey veterans affairs medical center. participants of this study are consented for the study, randomized into one of two treatment groups for hand osteoarthritis, both expected to improve hand symptoms. at the beginning of the study, many questionnaires, a physical exam, photographs of the hands, some x-rays, on a limited few people, and mri will be obtained. then the participants will be provided treatments for hand osteoarthritis based on the group wo which they were randomly assigned. one aspect of one of the treatments is viewed as experimental but the risks related to the treatment are considered to be low, so the risk-benefit ratio for participation in this study are good. we see patients in follow up more frequently during the first month, and then at 3 months and then 6 months of follow up. at the final visit, we will repeat the xrays and the mris.

Eligibility criteria:
inclusion criteria: * enrolled to receive medical care at the michael e. debakey va medical center * at least 3 joints affected by distal interphalangeal (dip) nodal hand oa * dip nodal hand oa will be defined as heberden's nodes on physical exam. * sufficiently severe frequent pain of at least one dip * frequent pain: pain on most days of the month for at least one month in the last year. * minimum vas pain severity of 40 on a 0 - 100 scale exclusion criteria: * history or current inflammatory arthritides (examples: gout, psoriatic arthritis, and rheumatoid arthritis) * prior surgery on the dip joints * planned surgery for the dip joints * pregnancy
a community intervention trial of multimodal suicide prevention program in japan (nocomit-j)

Conditions: Suicide

Summary: 1. the primary goal for this study is to examine the effectiveness of community-based multimodal intervention program for suicide prevention in relatively high suicide rate region compared to control region. 2. the secondary goal for this study is to explore the effectiveness of community-based multimodal intervention program for suicide prevention in the highly populated regions. in addition, we examine the effectiveness of the prevention program in the all regions combined.

suicide is a major public health problem and the number of suicide victims has exceeded 30,000 a year since 1998 in japan. suicide rate is almost 25/100,000, which are remarkably high numbers among advanced countries. to examine the effectiveness of community-based multimodal intervention program for suicide prevention, a trial by j-misp (japanese multimodal intervention trials for suicide prevention). this research project is one of the strategic research projects funded by the japanese ministry of health, labor and welfare.

Eligibility criteria:
inclusion criteria: * areas which meet the following criteria are eligible for this study; * an area with firm support from local government and other organizations to conduct this multimodal suicide prevention program * an area capable to select intervention and control regions * an area capable to follow the data collection procedure described in the protocol * an area with comparable baseline data on suicide attempts rate in intervention and control region * an area with comparable baseline data on demographics in intervention and control region exclusion criteria: * none

Keywords: suicide, prevention community
effect of weight loss on brain insulin sensitivity in humans

Conditions: Insulin Resistance

Summary: obesity if known to be associated with brain insulin resistance in humans. this condition has not only implication for the brain but also for whole-body energy homeostasis. research in rodents indicates that weight loss is able to improve insulin sensitivity of the brain. the current project will test this hypothesis in humans. therefore, brain insulin sensitivity will be assessed by fmri in combination with intranasal insulin administration, using an established protocol. furthermore, effects of daily administration of insulin nasal spray (versus placebo) over 8 weeks will be assessed as secondary (exploratory) variables.


Eligibility criteria:
inclusion criteria: * hba1c \<6.5% * age between 40 and 75 years * no intake of antidiabetic drugs or drugs for weight reduction * no steroid intake * stable medication over 10 weeks before the start of the study exclusion criteria: * persons who wear non-removable metal parts in or on the body. * persons with reduced temperature sensitivity and / or increased sensitivity to heating of the body * cardiovascular disease can not be ruled out, e.g. manifest coronary heart disease, heart failure greater than nyha 2, previous heart attack, stroke condition * persons with hearing impairment or increased sensitivity to loud noises * people with claustrophobia * minors or non-consenting subjects are also excluded * subjects with an operation less than 3 months * simultaneous participation in other studies * neurological and psychiatric disorders * subjects with hemoglobin hb \<11 g / dl * hypersensitivity to any of the substances used
return to sport and functional performance following surgical intervention for anterior glenohumeral instability

Conditions: Anterior Shoulder Dislocation; Anterior Shoulder Instability

Summary: the purpose of this prospective cohort study is to compare patient-reported, clinical, and functional outcomes in patients who have elected to have either the bankart with remplissage or latarjet procedure for the treatment of anterior glenohumeral instability (aghi) up to 24-months postoperative.

the purpose of this prospective cohort study is to compare patient-reported, clinical, and functional outcomes in patients who have elected to have either the bankart with remplissage or latarjet procedure for the treatment of aghi up to 24-months postoperative. a secondary objective aims to address rates of return to sport (rts) and performance in an rts assessment in athletic patients with anterior glenohumeral instability (aghi) who elect to undergo either surgical intervention until 24-months postoperative.

Eligibility criteria:
inclusion criteria: * aged 18 - 50 years * documented reduction of anterior shoulder dislocation * patient has suffered two or more dislocations of the study shoulder * physical examination elicits unwanted glenohumeral translation with reproduction of symptoms * glenoid bone loss defined on ct (or mri) using standardized and reproducible best-fit circle techniques \< 25% * able to benefit from surgical intervention exclusion criteria: * glenoid defect in the affected shoulder ≥ 25% of the ap diameter of the glenoid * previous surgery on affected shoulder (any type of shoulder surgery) * significant shoulder comorbidities including osteoarthritis or other shoulder conditions including multi-directional instability * participant is involved in litigation or a workplace insurance claim (i.e., wcb). * confirmed connective tissue disorder (i.e., ehlers-danlos, marfans) * beighton hypermobility score of \>6 * active joint or systemic infection, significant muscle paralysis, rotator cuff tear arthropathy, charcot's arthropathy, significant medical comorbidity that could alter the effectiveness of the surgical intervention (e.g., cervical radiculopathy, polymyalgia rheumatica) * major medical illness (life expectancy less than 1 year) or unacceptably high operative risk * epilepsy * any condition that precludes informed consent (i.e. psychiatric illness) * unable to speak or read english/french * unable or unwilling to be followed for 2 years or complete functional testing

Keywords: bankart repair remplissage latarjet coracoid transfer return to sport
immunogenicity and safety of meningococcal acwy conjugate vaccine in healthy subjects from 2 to 18 years in taiwan

Conditions: Bacterial Meningitis

Summary: this study will evaluate the immunogenicity and safety of a single injection of novartis meningococcal acwy conjugate vaccine in healthy subjects from 2 to 18 years in taiwan.


Eligibility criteria:
inclusion criteria: 1. healthy subjects from 2 up to and including 18 years of age 2. who are in good health as determined by : medical history, physical exam,clinical judgment of the investigator, who have a negative urine pregnancy test for female subjects ≥11 years of age exclusion criteria: individuals not eligible to be enrolled in the study were those: 1. who had a previous confirmed or suspected disease caused by n. meningitidis. 2. who had household contact with and/or intimate exposure to an individual with culture-proven n. meningitidis infection within 60 days prior to enrolment. 3. who have previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s) (licensed or investigational). 4. who have received any vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrolment in this study or who are planning to receive any vaccine within 30 days from the study vaccines. 5. who have experienced within the 7 days prior to enrolment significant acute infection or have experienced fever within 3 days prior to enrolment. 6. who have any serious acute, chronic or progressive who have epilepsy or any progressive neurological disease or history of guillain-barre syndrome. 7. who have a history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine components. 8. who have a known or suspected impairment/alteration of immune function, either congenital or acquired 9. who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time. 10. who have down's syndrome or other known cytogenic disorders.

Keywords: meningococcal acwy bacterial meningitis conjugate vaccine healthy children adolescents taiwan
a retrospective, multicenter, controlled clinical trail: to evaluate the clinical efficiency of intracranial aneurysm assistive software in the morphological measurement

Conditions: Intracranial Aneurysm

Summary: the goal of this clinical trail is to evaluate the clinical efficiency of intracranial aneurysm assistive software in the morphological measurement. the trail is designed as retrospective, multicenter, controlled clinical trail. collecting probable cases images retrospectively according to inclusion criteria and exclusion criteria strictly. controlling bias strictly, to make sure the measurement of intracranial aneurysm assistive software is evaluated reliably and precisely. in our trail, six physicions were recruited, containing three neuroradiologists, two radiologists and a residents. software-assistant planning controls against no software-assisant planning，which aims to evaluate the improvement of morphological measurement efficiency of physicians.


Eligibility criteria:
inclusion criteria: 1. aged 18-75y, no gender limitation. 2. non-ruptured intracranial saccular aneurysm with specific intracranial cta images. 3. intracranial aneurysm was not treated. inclusion criteria of images: 1. the number of detector rows of computed tomography(ct) is more than 16 rows. 2. slice thickness ≤ 0.625mm, whole-brain image is considered. 3. both plain scan sequences and enhancer sequence are required. exclusion criteria: 1. combined with cerebral hemorrhage; 2. combined with cerevascular malformation or cerebral occupying lesion; 3. fusiform aneurysm or dissection aneurysm; 4. intracaverous internal carotid artery aneurysm; exclusion criteria of images: 1. none dicom format; 2. quality score less than 3 scores; 3. metal artifacts existance.

Keywords: intracranial aneurysm artificial intelligence morphological measurement
tircon international nbia registry

Conditions: Neurodegeneration With Brain Iron Accumulation (NBIA); Pantothenate Kinase-associated Neurodegeneration (PKAN); Beta-Propeller Protein-Associated Neurodegeneration (BPAN); Mitochondrial Membrane Protein Associated Neurodegeneration (MPAN); Fatty Acid Hydroxylase-associated Neurodegeneration (FAHN); Kufor Rakeb Syndrome; Neuroferritinopathy; Aceruloplasminemia; Woodhouse Sakati Syndrome; COASY Protein-associated Neurodegeneration (CoPAN); PLA2G6-Associated Neurodegeneration (PLAN)

Summary: tircon-reg aims to * continue the provision of a global registry and natural history study for nbia disorders * harmonize and cover existing national and single site registries * enable participation of countries and single sites that so far have no access to an nbia registry * join forces in order to recruit sufficient numbers of patients * define the natural history of nbia disorders * define the most appropriate outcome measures * inform the design and facilitate the conduction of clinical trials

the tircon international patient registry and natural history study for patients with neurodegeneration associated with brain iron accumulation (nbia) was initiated and funded for the first four years by tircon (treat iron-related childhood-onset neurodegeneration), an international consortium supported by the european union between november 1st 2011 and october 31st, 2015. since then, the registry has been sustained through donations form patient organizations and industry. harmonization of existing data has been performed by establishing and applying matching and transformation rules. the web-based registry is now fully functional for a critically needed natural history study of all nbia subtypes. a focus has been set on scores that are most appropriate to reflect stage and progression of disease, e.g. the barry albright dystonia scale, the patient´s global impression of improvement (pgii), the unified parkinson disease rating scale (updrs; parts i-iii and vi) and quality-of-life scores. the natural history data are collected yearly, or in rapidly progressing cases every six months, if applicable. patients who present to one of our centers are eligible after informed consent to participate.

Eligibility criteria:
inclusion criteria: * suspected or confirmed nbia * willingness to participate exclusion criteria: * unwillingness to participate

Keywords: nbia, pkan, bpan, mpan, fahn, krs, copan, plan,
cyanoacrylate and laser and dentin sensitivity

Conditions: Dentin Hypersensitivity; Dentin Sensitivity

Summary: this study aimed to evaluate the effectiveness of two treatments for dental hypersensitivity: cyanoacrylate (super bonder®) compared with use of low intensity laser treatment (lilt). as the cyanoacrylate is a lower cost treatment, the hypothesis in investigation is if this product is equally effective as the laser treatment.

the present study included 62 patients (15 male and 47 females, aged 12 to 60 years). the initial cervical dentin hypersensitivity was checked throughout a thermal test (air blast). the 434 teeth included were that with a score ≥5 in a numerical scale rating of pain. teeth were randomly assigned according quadrants (split mouth design) - 216 were allocated to lilt group and 218 for the super bonder® group. thermal tests with a tetrafluoroethane spray (endo-ice®) and air blast were performed and considered as baseline. pain parameters were recorded using a numerical scale rating with 24 hours, 30, 90 and 180 days after the interventions. quality of life of the patients was also assessed with the use of ohip-14 at baseline and after 180 days.

Eligibility criteria:
inclusion criteria: 1. patients should be in good general and dental health; 2. present complaints of dental sensitivity to cold, sweet, acidic foods and brushing; 3. present complaints of pain in teeth located in different quadrants; 4. manifest pain or discomfort upon application of the triple syringe air jet; 5. not be in current use of desensitizing agents. exclusion criteria: 1. presence of extensive restorations and carious lesions in the sensitive teeth; 2. undergoing orthodontic treatment; 3. frequent use of analgesics, antidepressants and anti-inflammatory drugs; 4. presence of gingival inflammation; 5. non-consent of patient.

Keywords: dentin hypersensitivity cyanoacrylate laser
clinical safety trial of long-term intermittent use of helioblock® sx cream

Conditions: Sunburn

Summary: the purpose of this study is to determine the safety potential of helioblock® sx cream as a sunscreen product in long term intermittent use conditions among pediatric subjects.. each subject will be enrolled to participate for six months. the test product should be applied every day that outdoor activities are planned, prior to any significant sun exposure during out-door activities (such as the beach, outdoor sport activities), or whenever the subject needs to be protected against sunburn or other damage due to the sun. a minimum of 14 days test product use and sun exposure is required.


Eligibility criteria:
inclusion criteria: * male or female subjects of any race or skin type, 6 months to 12 years of age inclusive, willing to use the test product intermittently for six months during outside activities exclusion criteria: * subjects with known sensitivities to any of the study ingredients or subjects with a condition or in a situation, which in the investigator's opinion, may suggest a significant hazard for the subject, may confound the study results, or interfere with the subject's participation in the study. * subjects who are pregnant or lactating
efficacy of ulinastatin for reducing radiation-induced oral mucositis in nasopharyngeal carcinoma patients

Conditions: Oral Mucositis (Ulcerative) Due to Radiation

Summary: this is a phase 3, open-label, multicenter, randomized controlled phase iii clinical trial. the purpose of this study is to evaluate the efficacy of ulinastatin, a kind of protease inhibitor, in the treatment of radiation-induced acute oral mucositis in localregionally advanced nasopharyngeal carcinoma(npc) patients treated with concurrent chemoradiotherapy(ccrt). to explore a new and efficient way to reduce the incidence and severity of radiation-induced acute oral mucositis.

radiation-induced acute oral mucositis (rtom) in nasopharyngeal carcinoma (npc) patients treat with concurrent chemoradiotherapy (ccrt) is common. currently, there is no effective treatment for rtom. ulinastatin, is a kind of natural anti-inflammatory substance. and this substance is insufficient when the body's inflammatory response is strongly. there are a series of studies have confirmed the efficacy and safety of ulinastatin in the treatment of body's inflammatory response. from the observation of our previous clinical practice, we found that ulinastatin can relieve the severity of rtom. the present study is undertaken to evaluate the efficacy of ulinastatin in the treatment of rtom in localregionally advanced npc patients treated with ccrt.

Eligibility criteria:
inclusion criteria: * newly histologic diagnosis of nasopharyngeal carcinoma without distant metastasis * clinical stage iii\~iva( uicc (union international against cancer) /ajcc (american joint committee on cancer) tnm staging system 8th edition) * karnofsky performance status scale between 80-100 * wbc count ≥ 4×109/l，neutrophil differential count≥ 1.5×109/l,hemoglobin ≥ 90g/l， platelet count ≥ 100×109/l * alt or ast ≤2.5×uln,bilirubin ≤2.5×uln,serum creatinine ≤1.5×uln or serum creatinine clearance≥60ml/min * sign the informed consent. exclusion criteria: * angle of sexual squamous cell carcinomas and basal cell layout, squamous cell carcinomas * younger than 18 years old or older than 70 years old * pregnancy or lactation * severe cerebrovascular disease/canker/psychosis/uncontrolled diabetes * have suffered from other tumor or now suffering from other tumor * have suffered from oral diseases or salivary gland diseases or mow suffering from oral diseases or salivary gland diseases * refuse to give up smoking/drinking/betel chewing * suffering from other active infection diseases and in need of treatment.

Keywords: ulinastatin radiation-induced acute oral mucositis localregionally advanced nasopharyngeal carcinoma intensity modulated radiation therapy